Drugs / Loncastuximab Tesirine
Loncastuximab Tesirine
also known as
ADCT-402 · ADCT-402 TESIRINE · Lonca · Loncastuximab tesirina · loncastuximab tesirine-lpyl · MT-2111 · Zynlonta
Other / unclassified targets CD19 via depletion
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved · conditional | EU (EMA) | Zynlonta | — | 2022-12-20 | europa.eu ↗ |
Trials 33 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06607549 | Mar 2025 → Nov 2029 expected | central nervous system non-hodgkin lymphoma | University of Utah | Recruiting | No outcome recorded |
| Phase 1 | NCT05971251 | Dec 2023 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05660395 | Jul 2023 → Jun 2026 | high grade B-cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT05228249 | Apr 2023 → Oct 2025 | high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05270057 | Jan 2023 → May 2025 overdue | Burkitt lymphoma | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05053659 | Jun 2022 → Nov 2026 expected | non-Hodgkin lymphoma | Paolo Caimi, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04970901 | Jun 2022 → Mar 2027 expected | B-cell non-Hodgkin lymphoma | ADC Therapeutics S.A. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04974996 | Feb 2022 → Mar 2024 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03685344 | Feb 2019 → Oct 2020 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT02669264 | Mar 2016 → Jul 2018 | acute lymphoblastic leukemia | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT02669017 | Mar 2016 → Feb 2019 | B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma +3 | ADC Therapeutics S.A. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07573436 | Jun 2026 → Jun 2030 expected | post-transplant lymphoproliferative disease | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05658562 | Jan 2023 → Aug 2028 expected | diffuse large B-cell lymphoma | Tanabe Pharma Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03684694 | Dec 2018 → Nov 2022 | diffuse large B-cell lymphoma, mantle cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT06919939 | Jan 2026 → Jan 2031 expected | diffuse large B-cell lymphoma, large B-cell lymphoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT07197307 | Oct 2025 → Jan 2030 expected | high grade B-cell lymphoma | University of Münster | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06788964 | Aug 2025 → Mar 2027 expected | large B-cell lymphoma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT05672251 | Jan 2024 → Mar 2027 expected | Richter transformation, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05453396 | Aug 2023 → May 2026 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT06918912 | Jun 2023 → Mar 2025 overdue | high grade B-cell lymphoma | Istituto Clinico Humanitas | Recruiting | No outcome recorded |
| Phase 2 | NCT05600686 | May 2023 → Oct 2026 expected | diffuse large B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2 | NCT05464719 | Sep 2022 → Jan 2030 expected | large B-cell lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05144009 | Jun 2022 → Jan 2024 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT05296070 | Jun 2022 → Jun 2028 expected | marginal zone lymphoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT05222438 | Apr 2022 → Dec 2025 | diffuse large B-cell lymphoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT05249959 | Mar 2022 → Mar 2026 overdue | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT05190705 | Feb 2022 → May 2026 overdue | Waldenstrom macroglobulinemia | Shayna Sarosiek, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04998669 | Feb 2022 → Aug 2027 expected | follicular lymphoma | Juan P. Alderuccio, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT04699461 | Nov 2021 → Nov 2022 | follicular lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT03589469 | Aug 2018 → May 2020 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05991388 | May 2024 → May 2031 expected | B-cell non-Hodgkin lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04384484 | Sep 2020 → Mar 2026 overdue | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04705454 | — | relapsed/refractory diffuse large B-cell lymphoma | ADC Therapeutics S.A. | No longer available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Loncastuximab Tesirine | “Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.” PMID 32012214 ↗ Feb 202030 |
| Known as | ADCT-402 | “Based on published results we considered the expected 12-month PFS with available treatments to be \<20%; we hypothesized that, in this setting of patients, a consolidation...” NCT05249959 ↗2“The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse...” NCT03685344 ↗ |
| Known as | ADCT-402 TESIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Known as | Lonca | “Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor...” PMID 37646659 ↗ Apr 2024 |
| Known as | Loncastuximab tesirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Known as | loncastuximab tesirine-lpyl | “Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor...” PMID 37646659 ↗ Apr 2024 |
| Known as | MT-2111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658562 ↗ |
| Known as | Zynlonta | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Action | Deplete | “Loncastuximab tesirine has been designed to target and kill CD19-expressing malignant B-cells.” NCT03589469 ↗ |
| Modality | Other / unclassified | “Loncastuximab tesirine is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19)” NCT03589469 ↗ |
| Route | Intravenous | “intravenous infusion” NCT02669017 ↗ |
| Target | CD19 | “comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers.” PMID 31685491 ↗ Nov 2019 |